AgomAb Therapeutics NVAGMB +0.85%14 PB Ratio is 4.16 as of Jul. 12, 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 62.88% on this metric.
The historical rank and industry rank for AgomAb Therapeutics NV's PB Ratio or its related term are showing as below:
AGMB'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.16
Current: 4.16
During the past 5 years, AgomAb Therapeutics NV's highest PB Ratio was 4.16. The lowest was 0.00. And the median was 0.00.
AGMB's PB Ratio is ranked worse than 62.88% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs AGMB: 4.16
During the past 12 months, AgomAb Therapeutics NV's average Book Value Per Share Growth Rate was -22.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 29.70% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of AgomAb Therapeutics NV was 29.70% per year. The lowest was 29.70% per year. And the median was 29.70% per year.
Back to Basics: PB Ratio
AgomAb Therapeutics NV (NAS:AGMB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AgomAb Therapeutics NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
AgomAb Therapeutics NV (AGMB) has a PB Ratio of 4.16 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #774 out of 1231 companies in the Biotechnology industry, placing it in the top 62.9%.
Is AgomAb Therapeutics NV's PB Ratio too high?
AgomAb Therapeutics NV's current PB Ratio is 4.16. The Biotechnology industry median PB Ratio is 2.93. AgomAb Therapeutics NV's value of 4.16 is 42% above this industry median. Based on the distribution chart, AgomAb Therapeutics NV ranks #774 out of 1231 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's PB Ratio compare to DNA and ACRS?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #774 out of 1231 companies for PB Ratio. This places AgomAb Therapeutics NV in the lower half of its industry. The industry median PB Ratio is 2.93. AgomAb Therapeutics NV's value of 4.16 is 42% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AgomAb Therapeutics NV's current PB Ratio of 4.16 is 42% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AgomAb Therapeutics NV and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current PB Ratio is 4.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current PB Ratio of 4.16. The current PB Ratio is 4.16 and 42% above the Biotechnology industry median of 2.93. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current PB Ratio is 4.16 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 